| cut off level | non-conversion surgery group (n = 18) | conversion surgery group (n = 50) | p-value |
---|---|---|---|---|
Sex (M/F) | Â | 15/8 | 41/9 | 0.115 |
Age (years) |  | 63.5(30–78) | 66.5(25–75) | 0.928 |
Performance Status 0/1 | Â | 13/5 | 44/6 | 0.119 |
Tumor location (U/M/L/whole) | Â | 8/7/3/0 | 19/18/13/0 | 0.719 |
Macroscopic type (0/1/2/3/4/5) | Â | 0/1/6/11/0/0 | 0/2/24/24/0 | 0.560 |
Histological differentiation intestinal/diffuse | Â | 5/13 | 22/28 | 0.228 |
Distant metastatic site | ||||
 Hematogenous +/- |  | 7/11 | 18/32 | 0.827 |
 Lymphogenous +/- |  | 12/6 | 36/14 | 0.670 |
Multiple non-curative factors +/- | Â | 6/12 | 33/17 | 0.016 |
Yoshida’s Category 1/2 |  | 0/18 | 23/27 |  < 0.001 |
Albumin (g/dl) low/high | 3.8 | 12/6 | 25/25 | 0.223 |
CEA (ng/ml) low/high | 5 | 8/10 | 22/28 | 0.974 |
CA19-9 (U/ml) low/high | 37 | 5/13 | 20/30 | 0.356 |
NLR low/high | 3.1 | 3/15 | 28/22 | 0.004 |
PLR low/high | 189 | 7/11 | 26/24 | 0.340 |
LMR low/high | 3.7 | 13/5 | 20/30 | 0.019 |
CD4+ lymphocyte /Hpf low/high | 15 | 9/9 | 21/29 | 0.557 |
CD8+ lymphocyte /Hpf low/high | 34 | 16/2 | 38/12 | 0.246 |
Foxp3+lymphocyte /Hpf low/high | 9 | 8/10 | 22/28 | 0.974 |
CD68+ macrophage /Hpf low/high | 28 | 7/11 | 25/25 | 0.418 |
CD163+ macrophage /Hpf low/high | 35 | 3/15 | 25/25 | 0.013 |